Ulcerative Colitis | Treatment Algorithms: Claims Data Analysis | Pediatric | US | 2018
The primary goal of ulcerative colitis (UC) treatment is to induce and maintain remission with few to no clinical symptoms remaining. Conventional therapies (5-ASAs, corticosteroids) are typically used to treat mild to moderate UC, whereas intravenous and subcutaneous tumor necrosis factor-alpha (TNF-α) inhibitors are primarily reserved for moderate to severe disease refractory to conventional treatment or for first-line treatment of the most-severe disease. Takeda’s Entyvio, a cell adhesion molecule (CAM) inhibitor approved for adult UC, offers an alternative treatment option, especially for TNF-α-refractory patients; however, it is not approved for pediatric UC. Still, given the limited treatment options for pediatric UC patients who fail TNF-α inhibitors, physicians may turn to Entyvio for some patients. Indeed, the availability of newer agents will likely make the treatment landscape more complex.
QUESTIONS ANSWERED:
- What patient share do key therapies and brands garner by line of therapy in newly diagnosed pediatric UC patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed pediatric UC patients?
- What proportion of pediatric UC patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?
- What percentage of pediatric UC patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?
- What are the product-level compliance and persistency rates among drug-treated pediatric patients with UC?
PRODUCT DESCRIPTION:
Treatment Algorithms: Claims Data Analysis provides detailed analysis of brand usage across different lines of therapy using real-world patient-level claims data so that clients can accurately assess their source of business and quantify areas of opportunity for increasing their brand share.
Geographies: United States
Real-world data: Longitudinal patient-level claims data analysis
Key drugs covered: Remicade, Humira, Simponi, Entyvio, oral/rectal aminosalicylates, immunosuppressants
Key analysis provided:
- Brand useacross longitudinal patient sample.
- Newly diagnosed patient analysis.
- Treatment initiation and progression.
- Line of therapy analysis.
- Combination therapy analysis.
- Source of business for recently treated patients.
- Persistency and compliance analysis.
- Product-level patient flowcharts.
